Prosecution Insights
Last updated: November 20, 2026
Application No. 17/790,407

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Non-Final OA §102§112
Filed
Jun 30, 2022
Priority
Jan 10, 2020 — provisional 62/959,578 +2 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
775 granted / 1055 resolved
+13.5% vs TC avg
Strong +23% interview lift
Without
With
+23.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
54 currently pending
Career history
1111
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
18.7%
-21.3% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1055 resolved cases

Office Action

§102 §112
DETAILED ACTION Claims 1, 3-14, 16-18, 21, 25, 27, and 31 are currently pending in the instant application. Claims 1, 3-9, 13, 14, 17, 18, and 31 are rejected. Claims 10-12, 16, 21, 25, and 27 are withdrawn from consideration as being for non-elected subject matter. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 17 September 2026 has been entered. Election/Restrictions Applicant's election with traverse of Group I and the election without traverse of the species PNG media_image1.png 136 276 media_image1.png Greyscale in the reply filed on 10 October 2025 has been previously acknowledged. Applicant’s amendment filed 11 September 2026 has amended the claims to exclude the elected species DDL-127 as Rb in the elected species is aryl and the instant claims have been amended to exclude aryl from Rb. Therefore, the search and examination has now been extended to the compound PNG media_image2.png 138 246 media_image2.png Greyscale which is not allowable. Claims 1, 3-9, 13, 14, 17, 18, and 31 have been examined to the extent that they are readable on the compound: PNG media_image2.png 138 246 media_image2.png Greyscale . Claims 21, 25, and 27 are withdrawn as they are drawn to a non-elected group. Claims 10, 11, 12, and 16 are withdrawn claims as they do not read on the compound PNG media_image2.png 138 246 media_image2.png Greyscale . Specifically, claim 10 requires two Ra to be alkyl, however, the compound PNG media_image2.png 138 246 media_image2.png Greyscale only has one Ra. Claim 11 requires Ra to be hydrogen and Claims 12 and 16 require the NRa to be NH, wherein the compound PNG media_image2.png 138 246 media_image2.png Greyscale has NRa as NCH3. Response to Amendment and Arguments Applicant's amendment and arguments filed 11 September 2026 have been fully considered and entered. Applicant’s amendment has overcome the 35 USC 102(a)(1) rejection of claims 1, 3-9, 13, 14, 17, and 18 as being anticipated by Deb et al., Mol Divers (2012) 16: 803-823 as Rb has been amended to exclude aryl. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3, 4, 6-9, 13, 14, 17, 18, and 31 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claim 1 claims a compound of the formula I or a pharmaceutically acceptable salt thereof…wherein the compound is not PNG media_image3.png 84 138 media_image3.png Greyscale or a salt thereof. The provided out “salt” of the compound PNG media_image3.png 84 138 media_image3.png Greyscale renders the claims indefinite as it is unclear how any “salt” can be provided out as only formula I or its “pharmaceutically acceptable salt” is claimed. It is suggested that the “salt” in the proviso be amended to be “or a pharmaceutically acceptable salt thereof.” Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3-9, 13, 14, 17, and 31 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tadamasa Onaka, Tetrahedron Letters No. 46 , pp4391-4392, 1971. Tadamasa Onaka, Tetrahedron Letters No. 46 , pp4391-4392, 1971, discloses compounds of the formula I:, page 4391, specifically compound Ic: PNG media_image4.png 92 372 media_image4.png Greyscale which is the structure: PNG media_image2.png 138 246 media_image2.png Greyscale The compound Ic corresponds to formula I of instant claims, for example, instant claim 1, formula I: PNG media_image5.png 140 158 media_image5.png Greyscale wherein X1 is O; n is 1; X2 is NRa; Ra is alkyl, specifically C1alkyl; R1 is H; R2 is alkyl, specifically, C1alkyl; R4 is H; X3, X4, and X6 are each CR3 wherein R3 is hydrogen; and X5 is CR3 wherein R3 is alkoxy. The compound Ic reads on the formula Ib of claim 3. The compound Ic reads on the formula IIa of claim 4. The compound Ic reads on the formula IIIa of claim 5. The position equivalent to R1 is hydrogen in the compound Ic which reads on claim 6. The position equivalent to R2 is C1alkyl which reads on claim 7. A position equivalent to R3 is C1alkoxy which reads on claim 8. A position equivalent to an Ra is alkyl which reads on claim 9. The position equivalent to n is 1 which reads on claim 13. The position equivalent to R4 as hydrogen in the compound Ic reads on claim 14. In regards to claims 17 and 31, while Rb is limited in claims 17 and 31, Rb is not required to be present, therefore, the compound Ic reads on claims 17 and 31. Claim(s) 1, 3-9, 13, 14, 17, 18, and 31 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Registry No. 16641-65-9. Registry No. 16641-65-9 is PNG media_image2.png 138 246 media_image2.png Greyscale . Registry No. 16641-65-9 corresponds to formula I of instant claims, for example, instant claim 1, formula I: PNG media_image5.png 140 158 media_image5.png Greyscale wherein X1 is O; n is 1; X2 is NRa; Ra is alkyl, specifically C1alkyl; R1 is H; R2 is alkyl, specifically, C1alkyl; R4 is H; X3, X4, and X6 are each CR3 wherein R3 is hydrogen; and X5 is CR3 wherein R3 is alkoxy. Registry No. 16641-65-9 reads on the formula Ib of claim 3. Registry No. 16641-65-9 reads on the formula IIa of claim 4. Registry No. 16641-65-9 reads on the formula IIIa of claim 5. The position equivalent to R1 is hydrogen in Registry No. 16641-65-9 which reads on claim 6. The position equivalent to R2 is C1alkyl which reads on claim 7. A position equivalent to R3 is C1alkoxy which reads on claim 8. A position equivalent to an Ra is alkyl which reads on claim 9. The position equivalent to n is 1 which reads on claim 13. The position equivalent to R4 as hydrogen in Registry No. 16641-65-9 which reads on claim 14. In regards to claims 17 and 31, while Rb is limited in claims 17 and 31, Rb is not required to be present, therefore, Registry No. 16641-65-9 reads on claims 17 and 31. Registry No. 16641-65-9 is available as prior art as of 16 November 1984, the date it was indexed into the CAplus database. See MPEP 2128: ELECTRONIC PUBLICATIONS AS PRIOR ART Status as a "Printed Publication" An electronic publication, including an on-line database or Internet publication, is considered to be a “printed publication” within the meaning of 35 U.S.C. 102(a) and (b) provided the publication was accessible to persons concerned with the art to which the document relates. See In re Wyer, 655 F.2d 221, 227, 210 USPQ 790, 795 (CCPA 1981) Since this date represents the date that each compound entered the CAPlus database on STN, this represents the date that each compound was made accessible to the public. The aforementioned compound anticipates the instantly claimed compounds: It is further noted that for the purposes of determining if a reference is a “printed publication” for the purposes of 102(b), MPEP 2128 states the following: PNG media_image6.png 99 480 media_image6.png Greyscale where “prior art disclosures…on an on-line database are considered to be publicly available as of the date the item was publicly posted.” Since each of the database entries above lists the date that each compound was entered into the on-line database, the compounds were made publicly available as of that date in each citation, and the claims are anticipated. Regarding the composition of claim 18 comprising the anticipatory compound and a pharmaceutically acceptable carrier or excipient, the Registry entry for Registry No. 16641-65-9 discloses a mass solubility in unbuffered water. This teaching in of water anticipates the claimed composition, wherein the compounds are present with a carrier (i.e., water). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 3 November 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Jun 30, 2022
Application Filed
Oct 28, 2025
Non-Final Rejection mailed — §102, §112
Jan 28, 2026
Response Filed
May 13, 2026
Final Rejection mailed — §102, §112
Sep 11, 2026
Response after Non-Final Action
Sep 17, 2026
Request for Continued Examination
Sep 18, 2026
Response after Non-Final Action
Nov 05, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799154
PROCESS FOR PREPARING HIGH PURITY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF
5y 2m to grant Granted Nov 17, 2026
Patent 12799155
Process for the preparation of B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl) sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and intermediates of said process
3y 0m to grant Granted Nov 17, 2026
Patent 12799134
N-MACROCYCLIC AMIDE COMPOUNDS, PREPARATION METHODS THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
3y 5m to grant Granted Nov 17, 2026
Patent 12799128
KRAS INHIBITORS
2y 7m to grant Granted Nov 17, 2026
Patent 12790333
PIPERIDINYL-METHYL-PURINE AMINE D-TARTARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS
3y 5m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
97%
With Interview (+23.4%)
2y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1055 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month